Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

Health officials at the Africa Centres for Disease Control and Prevention (Africa CDC) today confirmed that the current Ebola outbreak in the Democratic Republic of the Congo and Uganda is being caused by the rare Bundibugyo strain.

Bundibugyo ebolavirus was first isolated during an outbreak of hemorrhagic fever in Uganda in 2007. There are no vaccines or specific treatments approved to prevent or treat the Bundibugyo strain.

Preliminary laboratory results from the Institut National de Recherche Biomedicale (INRB) detected Ebola virus in 13 of 20 samples tested with the Bundibugyo Virus.

"Africa CDC is actively collaborating with health authorities in DRC, Uganda, and regional partners to deliver a coordinated response to confirmed Ebola Virus Disease cases linked to the Bundibugyo strain," the Africa CDC said in a statement.

"Rapid laboratory testing, contact tracing, cross-border surveillance, and enhanced infection prevention measures are already deployed to protect communities and stop the spread," it added.

Ebola Outbreak: Cases And Deaths

As of the latest update from DRC, approximately 246 suspected cases and 65 deaths have been reported, mainly in Mongwalu and Rwampara health zones.

Four deaths have been reported among laboratory-confirmed cases.

Suspected cases have also been reported in Bunia and are pending confirmation. These figures remain provisional and are being validated through laboratory confirmation, line-list harmonization, contact identification, and epidemiological investigation.

Also read: Ebola Resurfaces In Eastern DR Congo In 17th Outbreak, Claims 65 Lives: All You Need To Know

Ebola Bundibugyo Virus Kills Ugandan Man

Uganda’s Ministry of Health, in a statement, reported a confirmed Ebola Bundibugyo Virus Disease case in a 59-year-old Congolese male who was admitted to Kibuli Muslim Hospital on May 11 and died on May 14.

The country's officials reported the case as imported from DRC and have indicated that no local case has yet been confirmed.

Africa CDC noted that it remains concerned by the urban context of Bunia and Rwampara, with intense population movement, insecurity, mining-related mobility in Mongwalu, gaps in contact listing, infection prevention and control challenges, and the proximity of affected areas to Uganda and South Sudan.

What Is Bundibugyo Virus Disease?

Bundibugyo virus disease is a rare and deadly illness that has caused outbreaks in several African countries in the past.

It is also spread by contact with contaminated objects (such as clothing, bedding, needles, and medical equipment), or by contact with animals, such as bats and nonhuman primates, that are infected with BVD.

Symptoms include fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising (a late stage of illness).

Read More: National Dengue Day 2026: India Reports 6,927 Cases And 10 Deaths In 2026

Ebola Outbreak: Here's How To Prevent

The US CDC advised people to avoid:

• contact with people who have symptoms such as fever, muscle pain, and rash
• contact with blood and other body fluids or objects that are contaminated with them
• visiting healthcare facilities in the affected areas for nonurgent medical care or for non-medical reasons. Avoid visiting traditional healers in the affected areas
• contact with dead bodies or items that have been in contact with dead bodies
• participating in funeral or burial practices that involve touching the body of someone who has died
• contact with bats, forest antelopes, nonhuman primates (e.g., monkeys, chimpanzees, gorillas), and blood, fluids, or raw meat from these or unknown animals.
• going into areas where bats live, such as mines or caves.

In case of infection, the CDC advises:

• Monitoring for symptoms of BVD while in the outbreak area and for 21 days after leaving.
• If you develop fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising (a late stage of illness)
• Isolate immediately
• Do not travel.
• Contact local health authorities

Even as the world is still grappling with the news of a hantavirus and two separate norovirus outbreaks, the Africa Centres for Disease Control and Prevention (Africa CDC) today confirmed that the Ebola virus has resurfaced in eastern Democratic Republic of the Congo for the 17th time.

In a statement, the Africa CDC reported that there are 246 suspected cases and 65 deaths, mainly in the mining areas of Mongwalu and Rwampara, about 100 kilometers north of the provincial capital, Bunia.

While tests are being carried out to identify the strain of the virus, early indications suggest the strain is not the Zaire variant, which has been responsible for several previous outbreaks in the country, the health officials said.

The Ebola Zaire strain was prominent in Congo’s past outbreaks, including the 2018 to 2020 outbreak in the eastern region that killed more than 1,000 people.

Ebola: 17th outbreak in DR Congo

Ebola was first discovered in 1976 in the DR Congo. This is the 17th outbreak of the deadly viral disease in the country.

As per preliminary tests conducted at the Institut National de Recherche Biomédicale (INRB) in the country's capital, Kinshasa, the Ebola virus has been detected in 13 of 20 samples analysed, following consultations with DR Congo's Ministry of Health and National Public Institute.

Of the 65 deaths, four were reported among lab-confirmed cases, Africa CDC said.

Additional suspected cases have also been reported in Ituri's provincial capital, Bunia, a densely populated urban centre near the borders with Uganda and South Sudan, raising fears of regional transmission.

All affected communities and at-risk areas have been advised to follow guidelines from the national health authorities.

Also read: More Americans Exposed To Hantavirus; 41 Under Monitoring, Says CDC

What Is Ebola Virus Disease?

As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal.

People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person, such as saliva, urine, feces, or semen, or things that have body fluids of an infected person, like clothes or sheets.

How Does Transmission Work?

Read More: Another Norovirus Outbreak Confirmed Aboard Cruise Ship In France; Over 1,700 People Trapped

Ebola enters the body through cuts in the skin or when one touches their eyes, nose, or mouth. Early symptoms include fever, fatigue, and headache.

It is a highly infectious and transmissible disease; in fact, there have been cases of healthcare workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.

Cases of people conducting burial ceremonies, involving direct contact with the body of the deceased, can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk or in pregnancy-related fluids and tissues.

Symptoms include:

• feeling tired
• headache
• muscle and joint pain
• eye pain and vision problems
• weight gain
• belly pain and loss of appetite
• hair loss and skin problems
• trouble sleeping
• memory loss
• hearing loss
• depression and anxiety.

Is There Any Vaccine for Ebola?

According to the WHO, there are two vaccines against the Ebola virus. But both the Merck-developed Ervebo vaccine, administered in one dose, and Johnson & Johnson-developed Zabdeno and Mvabea vaccine, administered in a two-dose regimen, target Zaire ebolavirus.

The Ervebo vaccine is recommended for use in outbreak settings and is currently the only vaccine available in the global stockpile.

The hantavirus outbreak may no longer be confined to the luxury Dutch cruise ship MV Hondius, with health officials now assessing the possibility of wider exposure. Officials at the US Centers for Disease Control and Prevention (CDC) said that although no cases have been reported in the US so far, the agency is monitoring 41 people for possible exposure.

The 41 includes the 18 people evacuated from the hantavirus-hit ship from Spain’s Canary Islands.

Notably, of the 18 passengers evacuated, two were carried in the plane's biocontainment units out of an abundance of caution — one who tested positive and another considered a suspected case. They were quarantined at a special facility in Nebraska. The remaining 16 are being quarantined in Omaha and Atlanta.

Speaking to CNN from a biocontainment unit at the University of Nebraska Medical Center in Omaha, Dr. Stephen Kornfeld of Oregon said he “feels wonderful” and is not experiencing symptoms.

Spanish officials confirmed that after initially testing positive for hantavirus, Dr. Kornfeld has since tested negative twice for the disease, meaning no Americans currently have the illness, Forbes reported.

CDC Monitoring More People

However, an additional 16 people are being monitored by the CDC.

The new individuals were not on the cruise ship but were passengers on an April 25 flight to Johannesburg and were exposed to someone known to have been infected, said Dr. David Fitter, who is leading the CDC response to the outbreak, according to The New York Times.

Also read: Shocking Study Finds Andes Hantavirus Could Linger In Semen For Years, Pose Transmission Risk

Seven other passengers from the cruise ship had disembarked on April 24 in St. Helena, an island in the Atlantic Ocean, returned to the US on commercial flights, and are being monitored by state health departments.

As of May 14, there were no confirmed hantavirus cases in the United States, Dr. Fitter said.

“Our job is to ensure that we are monitoring and in contact with anybody that might have been on the flight this person had taken,” Dr. Fitter told reporters. The agency is “monitoring all Americans that potentially would have been exposed, whether in the US or abroad, and we have been in contact with them,” he said.

Hantavirus Outbreak: 11 Cases And 3 Deaths Reported

According to the World Health Organization (WHO), 10 people have been affected by the rat-borne virus so far, of whom three have died.

A Dutch couple is believed to have first been exposed to the virus while visiting a birdwatching site in Argentina.

The WHO has confirmed that the Andes strain of hantavirus — the only strain known to spread from person to person — is behind the outbreak.

While all passengers onboard the cruise have been taken care of by health authorities, the virus’ long incubation period remains a serious concern. This means that even asymptomatic individuals could potentially become infectious 6-8 weeks later.

WHO Guidelines On Hantavirus Exposure

The WHO recommends that people exposed to hantavirus should be:

• Monitored actively at a specified quarantine facility
• Monitored at home for 42 days from the last exposure